1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > Global Biomarker Partnering 2010-2015: Deal trends, players, financials and forecasts

Summary
Global Biomarker Partnering 2010-2015: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Description

The Global Biomarker Partnering 2010-2015: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in biomarker partnering deals
Biomarker partnering agreement structure
Biomarker partnering contract documents
Top biomarker deals by value
Most active biomarker dealmakers

The Global Biomarker Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 650 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Global Biomarker Partnering 2010-2015 includes:

Trends in biomarker dealmaking in the biopharma industry since 2010
Analysis of biomarker deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life biomarker deals
Access to several biomarker contract documents
The leading biomarker deals by value since 2010
Most active biomarker dealmakers since 2010
The leading biomarker partnering resources

In Global Biomarker Partnering 2010-2015, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Biomarker Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 650 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise biomarker rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Biomarker Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of biomarker deal trends since 2010
Analysis of the structure of biomarker agreements with numerous real life case studies
Comprehensive access to over 650 actual biomarker deals entered into by the world’s biopharma companies, together with real world clause examples
Full listing of biomarker deals by company A-Z, deal value, phase of development, deal type, and therapy focus
Identify leading biomarker deals by value since 2010
Identify the most active biomarker dealmakers since 2010
Detailed access to actual biomarker deals and contracts enter into by the leading fifty big pharma companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Keywords

biomarker, personalized medicine, companion diagnostics, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Global Biomarker Partnering 2010-2015: Deal trends, players, financials and forecasts
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in biomarker dealmaking

2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Biomarker partnering by deal type
2.4. Biomarker partnering by industry sector
2.5. Biomarker partnering by stage of development
2.6. Biomarker partnering by disease type

Chapter 3 - Average financial deal terms for biomarker partnering

3.1. Introduction
3.2. Disclosed financials terms for biomarker partnering
3.3 Biomarker partnering headline values
3.4 Biomarker upfront payments
3.5 Biomarker milestone payments
3.6 Biomarker royalty rates

Chapter 4 - Leading biomarker deals

4.1. Introduction
4.1. Most active in biomarker partnering
4.2. Top biomarker deals by value
4.3. Big pharma biomarker dealmaking activity
4.4. Big biotech biomarker dealmaking activity

Chapter 5 - Biomarker contracts directory

5.1. Introduction
5.2. Biomarker partnering by company A-Z
5.3. Biomarker partnering stage of development
5.4. Biomarker partnering by deal type

Chapter 6 - Future trends and companies in biomarker deal making

6.1. Introduction
6.2. Future partnering trends predicted for biomarker deals
6.3. Emerging companies to watch in 2015
6.4. Emerging companies dealmaking in 2010-2015
6.5. Emerging company financings in 2010-2015
6.6 Conclusion

Appendices

Introduction
Appendix 1 - Directory of biomarker deals by company A-Z 2010-2015
Appendix 2 - Directory of biomarker deals by stage of development 2010-2015
Appendix 3 - Directory of biomarker deals by deal type 2010-2015
Appendix 4 - Directory of biomarker deals by therapy area 2010-2015
Appendix 5 - The anatomy of biomarker partnering
A.5.1 The anatomy of a biomarker deal
A.5.1.a Case study 1: Arno Therapeutics, Invivis Pharmaceuticals - February 2012

Appendix 6 - Antibody partnering resource center

Online antibody partnering
Biomarker partnering events
Further reading on biomarker dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Reports

Table of figures

Figure 1: Biomarker partnering since 2010
Figure 2: Biomarker partnering by deal type since 2010
Figure 3: Biomarker partnering by industry sector since 2010
Figure 4: Biomarker partnering by stage of development since 2010
Figure 5: Biomarker partnering by disease type since 2010
Figure 6: Biomarker deals with a headline value by year- 2015
Figure 7: Biomarker deals with a headline value by year- 2014
Figure 8: Biomarker deals with a headline value by year- 2013
Figure 9: Biomarker deals with a headline value by year- 2012
Figure 10: Biomarker deals with a headline value by year- 2011
Figure 11: Biomarker deals with a headline value by year- 2010
Figure 12: Summary median upfront value by year, 2010-2015
Figure 13: Biomarker deals with an upfront value by year- 2015
Figure 14: Biomarker deals with an upfront value by year- 2014
Figure 15: Biomarker deals with an upfront value by year- 2013
Figure 16: Biomarker deals with an upfront value by year- 2012
Figure 17: Biomarker deals with an upfront value by year- 2011
Figure 18: Biomarker deals with an upfront value by year- 2010
Figure 19: Summary median upfront value by year, 2010-2015
Figure 20: Biomarker deals with a milestone value by year- 2015
Figure 21: Biomarker deals with a milestone value by year- 2014
Figure 22: Biomarker deals with a milestone value by year- 2013
Figure 23: Biomarker deals with a milestone value by year- 2012
Figure 24: Biomarker deals with a milestone value by year- 2011
Figure 25: Biomarker deals with a milestone value by year- 2010
Figure 26: Biomarker deals with a royalty rate value by year- 2015
Figure 27: Biomarker deals with a royalty rate value by year- 2014
Figure 28: Biomarker deals with a royalty rate value by year- 2013
Figure 29: Biomarker deals with a royalty rate value by year- 2012
Figure 30: Biomarker deals with a royalty rate value by year- 2011
Figure 31: Biomarker deals with a royalty rate value by year- 2010
Figure 32: Summary median royalty rate by year, 2010-2015
Figure 33: Active biomarker dealmaking activity- 2010 to 2015
Figure 34: Top biomarker deals by value since 2010
Figure 35: Big pharma - top 50 - Biomarker deals 2010 to 2015
Figure 36: Big pharma biomarker deal frequency - 2010 to 2015
Figure 37: Big biotech - top 50 - Biomarker deals 2010 to 2015
Figure 38: Big biotech biomarker deal frequency - 2010 to 2015
Figure 39: Components of the typical biomarker deal structure
Figure 40: Online partnering resources
Figure 41: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Biobanking: Technologies and Global Markets

Biobanking: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

Use this report to: - Analyze the role biobanks play in the development of new drugs for specific disease treatments. - Learn about the prevailing market size for certain biobank services available ...

Cardiac Biomarkers Market By Type, By Application, By End Use, By Region And Segment Forecasts to 2024

Cardiac Biomarkers Market By Type, By Application, By End Use, By Region And Segment Forecasts to 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The cardiac biomarkers market is expected to reach USD13.3 billion by 2024, according to a new report by Grand View Research, Inc. The cardiac biomarkers market is anticipated to witness a lucrative growth ...

Cancer Biomarkers - Global Market Outlook (2016-2022)

Cancer Biomarkers - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Cancer Biomarkers market is estimated at $9215.32 million in 2015 and is expected to reach $20958.63 million by 2022 growing at a CAGR of 12.5% from 2015 to 2022. ...


Download Unlimited Documents from Trusted Public Sources

Genetic Industry in the US

  • November 2016
    10 pages
  • Genetic  

    Cardiovascular ...  

  • United States  

View report >

Genetic Industry in the UK

  • November 2016
    26 pages
  • Genetic  

  • United Kingdom  

    Europe  

View report >

Genetic Industry in the UK

  • November 2016
    26 pages
  • Genetic  

  • United Kingdom  

    Europe  

View report >

Related Market Segments :

Biomarker

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.